Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 11Completed 9Active not recruiting 4Unknown 3Terminated 3Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Turcot syndrome 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hodgkin Disease 2Glioblastoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Biliary Tract Neoplasms 2Advanced Endometrial Cancer 2Tongue Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous NSCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × pembrolizumab × Clear all
NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡